Haitian Program for Research and Training in HIV/AIDS

海地艾滋病毒/艾滋病研究和培训方案

• 批准号: 6732428
• 负责人: JEAN WILLIAM PAPE
• 金额: $ 53.4万
• 依托单位: GHESKIO CENTER
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-02-01 至 2006-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6732428
• 关键词: AIDS therapy; CD4 molecule; Caribbean islands; HIV infections; Mycobacterium tuberculosis; antiAIDS agent; clinical research; clinical trials; cooperative study; data management; disease /therapy duration; efavirenz; enzyme linked immunosorbent assay; ethics; flow cytometry; health science research support; human therapy evaluation; lamivudine; microorganism immunology; patient oriented research; sign /symptom; training; tuberculosis; zidovudine

DESCRIPTION (provided by applicant): The goal of this application is to prepare the GHESKIO Centers in Port-au-Prince, Haiti for a multi-project CIPRA in five years. This goal will be achieved through the conduct of a randomized clinical trial of early versus delayed antiretroviral therapy for people with pre-AIDS symptomatic HIV disease and through research training and capacity building. The GHESKIO Centers, directed by Jean Pape, is a Haitian non-governmental research and training organization working in close partnership with the Haitian Government on HIV/AIDS. Over the next five years, GHESKIO will become a regional HIV/AIDS center providing training and conducting research in collaboration with partners in Haiti and the Caribbean. The specific aims are: Aim 1: To determine the optimal time to start antiretroviral therapy (ART). We propose to conduct a randomized clinical trial to determine the outcome of early versus delayed antiretroviral therapy (ART) in HIV infected adults with pre-AIDS symptomatic HIV disease (WHO Sate II or III symptoms, such as pulmonary TB, chronic diarrhea, or oral thrush) and a CD4 count between 200 and 350 cells/mm3. The primary hypothesis is: Early initiation of ART in HIV infected adults with pre-AIDS symptoms and a CD4 count between 200 and 350 cells/mm3 will improve survival at 36 months when compared to delaying ART until subjects develop clinical AIDS (WHO stage IV) or CD4 count <200 cells/mm3. Aim 2: To build on the existing capacity of the GHESKIO Center in Port au Prince Haiti and to prepare for a multi-project CIPRA within five years. Capacity will be increased in: 1) Administration, including development of an advisory council, increasing ethics capacity, strengthening grants management, and strengthening training. 2) Clinical investigation; 3) Data management and analysis; 4) Laboratory capacity including HIV virology and immunology. In each of these capacity building areas, we have identified promising young Haitians who will participate in the CIPRA project and who will also receive advanced training and mentorship by senior investigators from the US. These Haitians will be leaders in a multi-project CIPRA in five years.

描述（由申请人提供）：本申请的目标是让位于海地太子港的 GHESKIO 中心在五年内为多项目 CIPRA 做好准备。 这一目标将通过对患有艾滋病前期症状的艾滋病毒患者进行早期与延迟抗逆转录病毒治疗的随机临床试验以及研究培训和能力建设来实现。 GHESKIO 中心由 Jean Pape 领导，是一个海地非政府研究和培训组织，与海地政府在艾滋病毒/艾滋病问题上密切合作。 未来五年，GHESKIO 将成为一个区域艾滋病毒/艾滋病中心，与海地和加勒比地区的合作伙伴合作提供培训和开展研究。 具体目标是： 目标 1：确定开始抗逆转录病毒治疗 (ART) 的最佳时间。 我们建议进行一项随机临床试验，以确定早期与延迟抗逆转录病毒治疗（ART）对患有艾滋病前症状性艾滋病毒疾病（WHO Sate II 或 III 症状，如肺结核、慢性腹泻或口腔溃疡）的 HIV 感染成人的结果。鹅口疮）和 CD4 计数在 200 至 350 个细胞/mm3 之间。 主要假设是：与延迟 ART 直至受试者出现临床艾滋病（WHO IV 期）相比，对有艾滋病前症状且 CD4 计数在 200 至 350 个细胞/mm3 之间的 HIV 感染成人尽早开始 ART 将提高 36 个月的生存率或 CD4 计数 <200 个细胞/mm3。 目标 2：利用海地太子港 GHESKIO 中心的现有能力，并在五年内为多项目 CIPRA 做好准备。 容量将增加： 1) 行政管理，包括建立顾问委员会、提高道德能力、加强赠款管理和加强培训。 2）临床调查； 3）数据管理与分析； 4）实验室能力，包括HIV病毒学和免疫学。 在每个能力建设领域，我们都已经确定了有前途的海地年轻人，他们将参与 CIPRA 项目，并接受来自美国高级调查人员的高级培训和指导。 这些海地人将在五年内成为多项目 CIPRA 的领导者。